AscellaHealth Presents Drug Reimbursement Strategies for 21st Century Cures: IDN & Bio/Pharma Partnering Summit

AscellaHealth Presents Drug Reimbursement Strategies for 21st Century Cures: IDN & Bio/Pharma Partnering Summit




AscellaHealth Presents Drug Reimbursement Strategies for 21st Century Cures: IDN & Bio/Pharma Partnering Summit

BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth, a global specialty pharmacy and healthcare solutions company, announces that it will present “Drug Reimbursement Strategies for 21st Century Cures” at the IDN and Bio/Pharma Partnering Summit, Aug. 19, 11:15 a.m.–12 p.m. EDT. The presentation will explore emerging trends in access and reimbursement during this virtual event, which is designed to explore high-impact topics among industry leaders and optimize strategic partnerships to improve access to care and patient outcomes.

“With a wave of highly durable and potentially curative therapies in the pipeline for diseases like hemophilia and sickle cell, this session addresses key questions about how to pay for high-cost therapies that promise to be transformative for patients and their families,” says Dea Belazi, president and CEO, AscellaHealth. “The market could soon see a manufacturer charging $5 million to cure a single hemophilia patient based on the lifetime cost savings to the payer. Given this potential, attendees will learn how the current reimbursement system is not designed to handle such large upfront costs for single dose therapies. While the need for alternative payment models is clearly needed, it’s equally important to explore what will become the gold standard for cell and gene therapies.”

Moderated by Michael Baldzicki, CRCM, executive vice president, Growth and Strategy, AscellaHealth, the session features Jeffrey Hogan, president, Upside Health Advisors, and Emad Samad, president, Octaviant Financial, Inc., who will explore 1) the use of warranties and pay-overtime models for high-cost therapies, 2) how to maintain a competitive edge in price negotiations and 3) making liabilities for high-cost drugs portable between payers.

Belazi adds, “We are looking forward to this important event, which serves as a think-tank for industry pioneers and showcases novel case studies and innovative partnership models that deliver enhanced value, manage costs and improve quality. AscellaHealth is committed to playing a crucial role in helping stakeholders manage drug benefits, lower costs and improve the quality of healthcare.”

About AscellaHealth LLC

AscellaHealth is a global Specialty Pharmacy and Healthcare services organization serving payers, providers, life sciences and patients, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and medical management services. AscellaHealth’s unique, patient-centric approach is built upon proprietary technology processes for innovative programs and services optimizing health outcomes and quality of life for patients with complex chronic conditions or rare diseases that require specialty medications and/or gene and cell therapies. Visit www.AscellaHealth.com.

Contacts

Media:
Nicole Dufour

CPR Communications

ndufour@cpronline.com
201.641.1911 x 54